DBV Technologies Reports $47.6 Million Net Loss in Q1 2026 Amid Increased R&D Expenses

DBV Technologies S.A. reported a net loss of $47.6 million for the first quarter of 2026, a significant increase from the $27.1 million loss recorded in the same period of 2025. The company's operating income rose slightly to $0.9 million, up from $0.8 million year-over-year, primarily driven by a research tax credit of $0.9 million. Total operating expenses surged to $48.8 million, an increase of 78% compared to $27.4 million in the prior year, reflecting heightened research and development activities as the company prepares for the potential U.S. launch of its Viaskin Peanut patch.

The increase in operating expenses was largely attributed to a 55% rise in research and development costs, which reached $33.4 million, up from $21.5 million in the previous year. This increase was driven by higher clinical trial activities, particularly the initiation of patient recruitment for the COMFORT Toddlers study, and preparations for the Biologics License Application (BLA) submission. Sales and marketing expenses also saw a dramatic increase, rising to $4.8 million from just $0.3 million, as the company builds its commercial infrastructure in anticipation of the product launch.

DBV Technologies' cash and cash equivalents stood at $229.2 million as of March 31, 2026, compared to $194.2 million at the end of 2025. The company reported net cash used in operating activities of $49.1 million for the first quarter, up from $19.7 million in the same period last year. This increase reflects the acceleration of clinical development activities and the expansion of the workforce. The company expects operating cash outflows to remain elevated as it advances toward BLA submission and invests in manufacturing readiness.

In terms of strategic developments, DBV Technologies entered into a Manufacturing Supply Agreement with Fareva La Vallée on March 17, 2026, for the exclusive supply of Viaskin peanut source material over an eight-year term. This agreement follows a previous service agreement for the construction of a dedicated production line. The company also completed a PIPE financing in March 2025, generating gross proceeds of $125.5 million, which has bolstered its financial position and supported ongoing development efforts.

Looking ahead, DBV Technologies aims to submit its BLA for the Viaskin Peanut patch in children aged 4 to 7 in the first half of 2026. The company is focused on advancing its commercialization strategy while managing its cash resources effectively. However, it cautions that the pace of cash utilization may vary based on regulatory interactions and clinical enrollment timelines, potentially necessitating additional financing sooner than anticipated.